Neuronetics Files 8-K on Financial Condition, Operations

TL;DR

**Neuronetics just dropped an 8-K on its financials, get ready for potential stock movement.**

AI Summary

Neuronetics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing, under SEC File Number 001-38546, indicates that the company, headquartered at 3222 Phoenixville Pike, Malvern, PA, is providing an update on its financial performance. For investors, this matters because it offers a timely glimpse into the company's health, potentially influencing stock price (STIM) based on whether the results meet or miss expectations.

Why It Matters

This filing provides investors with crucial, up-to-date information on Neuronetics' financial health, which can directly impact their investment decisions and the stock's performance.

Risk Assessment

Risk Level: medium — The risk is medium because while the filing itself is routine, the undisclosed financial details could contain positive or negative surprises for investors.

Analyst Insight

A smart investor would monitor for the actual financial results that this 8-K foreshadows, as the current filing only indicates an update is coming, not the details themselves.

Key Numbers

• 001-38546 — SEC File Number (identifies Neuronetics' registration with the SEC)
• 2024-01-08 — Date of Report (indicates the timeliness of the financial information)

Key Players & Entities

• Neuronetics, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Neuronetics, Inc.
• The Nasdaq Global Market (company) — exchange where Neuronetics' Common Stock is registered
• STIM (company) — trading symbol for Neuronetics, Inc. Common Stock
• January 8, 2024 (date) — date of earliest event reported and filing date
• 001-38546 (dollar_amount) — SEC File Number
• 3222 Phoenixville Pike, Malvern, PA 19355 (company) — address of principal executive offices
• 610-640-4202 (dollar_amount) — registrant's telephone number

Forward-Looking Statements

• Neuronetics will release detailed financial results soon, likely within the next few weeks. (Neuronetics, Inc.) — high confidence, target: 2024-02-29
• The stock price of STIM will react significantly to the specific financial figures once they are publicly disclosed. (STIM) — medium confidence, target: 2024-01-31

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global M

Filing Documents

• d291263d8k.htm (8-K) — 24KB
• d291263dex991.htm (EX-99.1) — 11KB
• g291263g0107055827714.jpg (GRAPHIC) — 5KB
• 0001193125-24-003966.txt ( ) — 163KB
• stim-20240108.xsd (EX-101.SCH) — 3KB
• stim-20240108_lab.xml (EX-101.LAB) — 17KB
• stim-20240108_pre.xml (EX-101.PRE) — 11KB
• d291263d8k_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Neuronetics, Inc., or the Company, issued a press release on January 8, 2024 announcing certain preliminary financial information for the three and twelve months ended December 31, 2023. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. *** The information furnished pursuant to Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, we undertake no duty or obligation to publicly update or revise the information so furnished.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated January 8, 2024, of Neuronetics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEURONETICS, INC. (Registrant) Date: January 8, 2024 By: /s/ Stephen Furlong Name: Stephen Furlong Title: SVP, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR